{"id":745355,"date":"2016-06-20T11:30:00","date_gmt":"2016-06-20T11:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-in-combination-with-imipenem-cilastatin-presented-at-asm-microbe\/"},"modified":"2025-11-07T01:25:45","modified_gmt":"2025-11-07T06:25:45","slug":"results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-in-combination-with-imipenem-cilastatin-presented-at-asm-microbe","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-in-combination-with-imipenem-cilastatin-presented-at-asm-microbe\/","title":{"rendered":"Results of Phase 2 Study of Merck\u2019s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem\/Cilastatin Presented at ASM Microbe"},"content":{"rendered":"<p class=\"bwalignc\">       Pivotal Phase 3 Studies Ongoing in Treatment of Serious Bacterial        Infections     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that a Phase 2 study of relebactam, the company\u2019s<br \/>\n      investigational beta-lactamase inhibitor, in combination with<br \/>\n      imipenem\/cilastatin (an approved carbapenem antibiotic), in patients<br \/>\n      with complicated urinary tract infections, met its primary endpoint. The<br \/>\n      addition of relebactam is designed to restore activity of imipenem<br \/>\n      against certain imipenem-resistant strains of Gram-negative bacteria,<br \/>\n      including <i>Pseudomonas aeruginosa<\/i> and <i>Klebsiella pneumoniae<\/i><br \/>\n      carbapenemase (KPC)-producing Enterobacteriaceae.\n    <\/p>\n<p>\n      The results were presented at the American Society for Microbiology\u2019s<br \/>\n      ASM Microbe 2016 meeting in Boston, June 16-20.\n    <\/p>\n<p>\n      \u201cNew medicines are urgently needed to address the growing threat of<br \/>\n      antibiotic-resistant bacteria,\u201d said Dr. Amanda Paschke, director,<br \/>\n      infectious disease clinical research, Merck Research Laboratories. \u201cWe<br \/>\n      look forward to advancing our Phase 3 clinical program evaluating<br \/>\n      relebactam in combination with imipenem for use in the treatment of<br \/>\n      several complicated Gram-negative bacterial infections, and to continue<br \/>\n      to build on Merck&#8217;s commitment to addressing infectious diseases.\u201d\n    <\/p>\n<p>\n      In this multicenter, double-blind Phase 2 study, 302 adult patients with<br \/>\n      complicated urinary tract infections (51.7%) or acute pyelonephritis<br \/>\n      (48.3%) were randomized to receive either relebactam 250mg, relebactam<br \/>\n      125mg, or placebo, each given intravenously (IV) in combination with<br \/>\n      imipenem\/cilastatin (IMI) 500mg every six hours for 4 to 14 days.<br \/>\n      Efficacy was evaluated at discontinuation of IV therapy (DCIV), early<br \/>\n      follow\u2010up, and late follow\u2010up. The primary endpoint was the proportion<br \/>\n      of microbiologically evaluable patients with a favorable microbiological<br \/>\n      response at DCIV, assessed by non\u2010inferiority testing with a 15% margin.<br \/>\n      Results were similar across treatment groups: relebactam 250mg + IMI<br \/>\n      (95.5%) (n=67), relebactam 125mg + IMI (98.6%) (n=71), and placebo + IMI<br \/>\n      (98.7%) (n=75). Among microbiologically evaluable patients, 10.5% (n=25)<br \/>\n      had imipenem-resistant Gram-negative infections at baseline.\n    <\/p>\n<p>\n      Safety analysis focused on adverse events occurring while on intravenous<br \/>\n      study therapy or during the 14 days following the end of therapy in all<br \/>\n      randomized patients who received at least one dose of intravenous study<br \/>\n      therapy. The most common adverse events (headache, diarrhea and nausea)<br \/>\n      occurred at similar rates across treatment groups: relebactam 250mg +<br \/>\n      IMI (7.1%, 5.1%, 4.0%), relebactam 125mg + IMI (3.0%, 2.0%, 6.1%), and<br \/>\n      placebo + IMI (4.0%, 4.0%, 4.0%), respectively.\n    <\/p>\n<p>\n      <b>Phase 3 Clinical Program of Relebactam\/Imipenem\/Cilastatin Ongoing<\/b>\n    <\/p>\n<p>\n      Two pivotal Phase 3 clinical studies of relebactam in combination with<br \/>\n      imipenem\/cilastatin are currently ongoing and recruiting patients. One<br \/>\n      study compares treatment with imipenem\/relebactam, as a fixed-dose<br \/>\n      combination, with piperacillin\/tazobactam in patients with<br \/>\n      hospital-acquired bacterial pneumonia or ventilator-associated bacterial<br \/>\n      pneumonia. The primary hypothesis of this study is that<br \/>\n      imipenem\/relebactam is non-inferior to piperacillin\/tazobactam in the<br \/>\n      incidence rate of all-cause mortality. (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02493764%3Fterm%3Drelebactam%26rank%3D2&amp;esheet=51363339&amp;newsitemid=20160620005016&amp;lan=en-US&amp;anchor=www.ClinicalTrials.gov+Identifier%3A+NCT02493764&amp;index=1&amp;md5=e4f5f2b3b0905bb9c9816b96fc4e5abb\" rel=\"nofollow\">www.ClinicalTrials.gov<br \/>\n      Identifier: NCT02493764<\/a>)\n    <\/p>\n<p>\n      A second study evaluates the efficacy and safety of imipenem\/relebactam<br \/>\n      versus colistimethate sodium in combination with imipenem in the<br \/>\n      treatment of imipenem-resistant bacterial infections, including those<br \/>\n      caused by<i> Pseudomonas aeruginosa<\/i> and KPC-producing organisms.<br \/>\n      Infections evaluated in this study include hospital-acquired bacterial<br \/>\n      pneumonia, ventilator-associated bacterial pneumonia, complicated<br \/>\n      intra-abdominal infections and complicated urinary tract infections. (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02452047%3Fterm%3Drelebactam%26rank%3D1&amp;esheet=51363339&amp;newsitemid=20160620005016&amp;lan=en-US&amp;anchor=www.ClinicalTrials.gov+Identifier%3A+NCT02452047&amp;index=2&amp;md5=559464a38f4727713c95b0fe41bfa6bc\" rel=\"nofollow\">www.ClinicalTrials.gov<br \/>\n      Identifier: NCT02452047<\/a>)\n    <\/p>\n<p>\n      <b>About Relebactam<\/b>\n    <\/p>\n<p>\n      Relebactam is an investigational, intravenous, class A and C,<br \/>\n      beta-lactamase inhibitor currently being evaluated in combination with<br \/>\n      imipenem\/cilastatin for the treatment of certain complicated<br \/>\n      Gram-negative bacterial infections. In preclinical studies, relebactam<br \/>\n      administered in combination with imipenem demonstrated antibacterial<br \/>\n      activity against a broad range of Gram-negative and<br \/>\n      beta-lactam-resistant pathogens. The U.S. Food and Drug Administration<br \/>\n      (FDA) has designated this combination as a Qualified Infectious Disease<br \/>\n      Product (QIDP) with designated Fast Track status for the treatment of<br \/>\n      hospital-acquired bacterial pneumonia, ventilator-associated bacterial<br \/>\n      pneumonia, complicated intra-abdominal infections and complicated<br \/>\n      urinary tract infections.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51363339&amp;newsitemid=20160620005016&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=5b6a28fd8a56f5777cf4a023a22ed6ac\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51363339&amp;newsitemid=20160620005016&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=4ddfea698c5b90aa4809fb12e510ba04\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51363339&amp;newsitemid=20160620005016&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=de62c26844d0e0944421f507f54116c2\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51363339&amp;newsitemid=20160620005016&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=88146c331a553cbd995415f4f04bc360\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51363339&amp;newsitemid=20160620005016&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=50ed7498115486487d6351a6ab6945f3\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51363339&amp;newsitemid=20160620005016&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=633b147ea71c57d69ba8a3c196cd62cd\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20160620005016r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, (267) 305-3558<br \/>or<br \/>Robert        Consalvo, (908) 295-0928<br \/>or<br \/>Investor:<br \/>Teri Loxam, (908)        740-1986<br \/>or<br \/>Amy Klug, (908) 740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pivotal Phase 3 Studies Ongoing in Treatment of Serious Bacterial Infections Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the company\u2019s investigational beta-lactamase inhibitor, in combination with imipenem\/cilastatin (an approved carbapenem antibiotic), in patients with complicated urinary tract infections, met its primary endpoint. The addition of relebactam is designed to restore activity of imipenem against certain imipenem-resistant strains of Gram-negative bacteria, including Pseudomonas aeruginosa and Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae. The results were presented at the American Society for Microbiology\u2019s ASM Microbe 2016 meeting in Boston, June 16-20. \u201cNew medicines are urgently needed to address the growing threat of antibiotic-resistant bacteria,\u201d said Dr. Amanda Paschke, director, infectious disease clinical research, Merck Research Laboratories. \u201cWe look forward<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-745355","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Results of Phase 2 Study of Merck\u2019s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem\/Cilastatin Presented at ASM Microbe - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-in-combination-with-imipenem-cilastatin-presented-at-asm-microbe\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Results of Phase 2 Study of Merck\u2019s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem\/Cilastatin Presented at ASM Microbe - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Pivotal Phase 3 Studies Ongoing in Treatment of Serious Bacterial Infections Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the company\u2019s investigational beta-lactamase inhibitor, in combination with imipenem\/cilastatin (an approved carbapenem antibiotic), in patients with complicated urinary tract infections, met its primary endpoint. The addition of relebactam is designed to restore activity of imipenem against certain imipenem-resistant strains of Gram-negative bacteria, including Pseudomonas aeruginosa and Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae. The results were presented at the American Society for Microbiology\u2019s ASM Microbe 2016 meeting in Boston, June 16-20. \u201cNew medicines are urgently needed to address the growing threat of antibiotic-resistant bacteria,\u201d said Dr. Amanda Paschke, director, infectious disease clinical research, Merck Research Laboratories. \u201cWe look forward\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-in-combination-with-imipenem-cilastatin-presented-at-asm-microbe\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-in-combination-with-imipenem-cilastatin-presented-at-asm-microbe\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-in-combination-with-imipenem-cilastatin-presented-at-asm-microbe\\\/\",\"name\":\"Results of Phase 2 Study of Merck\u2019s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem\\\/Cilastatin Presented at ASM Microbe - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-06-20T11:30:00+00:00\",\"dateModified\":\"2025-11-07T06:25:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-in-combination-with-imipenem-cilastatin-presented-at-asm-microbe\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-in-combination-with-imipenem-cilastatin-presented-at-asm-microbe\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-in-combination-with-imipenem-cilastatin-presented-at-asm-microbe\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Results of Phase 2 Study of Merck\u2019s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem\\\/Cilastatin Presented at ASM Microbe\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Results of Phase 2 Study of Merck\u2019s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem\/Cilastatin Presented at ASM Microbe - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-in-combination-with-imipenem-cilastatin-presented-at-asm-microbe\/","og_locale":"en_US","og_type":"article","og_title":"Results of Phase 2 Study of Merck\u2019s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem\/Cilastatin Presented at ASM Microbe - Merck.com","og_description":"Pivotal Phase 3 Studies Ongoing in Treatment of Serious Bacterial Infections Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the company\u2019s investigational beta-lactamase inhibitor, in combination with imipenem\/cilastatin (an approved carbapenem antibiotic), in patients with complicated urinary tract infections, met its primary endpoint. The addition of relebactam is designed to restore activity of imipenem against certain imipenem-resistant strains of Gram-negative bacteria, including Pseudomonas aeruginosa and Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae. The results were presented at the American Society for Microbiology\u2019s ASM Microbe 2016 meeting in Boston, June 16-20. \u201cNew medicines are urgently needed to address the growing threat of antibiotic-resistant bacteria,\u201d said Dr. Amanda Paschke, director, infectious disease clinical research, Merck Research Laboratories. \u201cWe look forward","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-in-combination-with-imipenem-cilastatin-presented-at-asm-microbe\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:45+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-in-combination-with-imipenem-cilastatin-presented-at-asm-microbe\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-in-combination-with-imipenem-cilastatin-presented-at-asm-microbe\/","name":"Results of Phase 2 Study of Merck\u2019s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem\/Cilastatin Presented at ASM Microbe - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-06-20T11:30:00+00:00","dateModified":"2025-11-07T06:25:45+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-in-combination-with-imipenem-cilastatin-presented-at-asm-microbe\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-in-combination-with-imipenem-cilastatin-presented-at-asm-microbe\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-in-combination-with-imipenem-cilastatin-presented-at-asm-microbe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Results of Phase 2 Study of Merck\u2019s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem\/Cilastatin Presented at ASM Microbe"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"affdda82-2497-482f-9d95-0d2cee675bf1","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Results-of-Phase-2-Study-of-Mercks-Investigational-Beta-Lactamase-Inhibitor-Relebactam-in-Combination-with-ImipenemCilastatin-Present-5I6JN.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745355\/revisions"}],"predecessor-version":[{"id":3674757,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745355\/revisions\/3674757"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745355"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}